The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.

Silberstein, Stephen D; Diener, Hans-Christoph; Dodick, David W; Manack Adams, Aubrey; DeGryse, Ronald E; Lipton, Richard B

Silberstein, Stephen D; Diener, Hans-Christoph; Dodick, David W; Manack Adams, Aubrey; DeGryse, Ronald E; Lipton, Richard B.

Afiliação

Silberstein SD; Thomas Jefferson University, Philadelphia, PA, USA. stephen.silberstein@jefferson.edu.
Diener HC; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
Dodick DW; Mayo Clinic, Phoenix, AZ, USA.
Manack Adams A; Allergan, an AbbVie Company, Irvine, CA, USA.
DeGryse RE; AbbVie, Irvine, CA, USA.
Lipton RB; Albert Einstein College of Medicine, Bronx, NY, USA.

Pain Ther ; 9(2): 695-707, 2020 Dec.

Article em En | MEDLINE | ID: mdl-33026630

Palavras-chave

Botulinum toxin type A; Chronic migraine; Headache; Quality of life

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Pain Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google